RNA Edge System
Optimizing expression of RNA therapies. Go from sequence to validated candidates in a matter of weeks.

A lab-in-the-loop platform for AI optimization of RNA therapeutic candidates
Expression profile is a primary determinant of therapeutic success, but most RNA sequences are still optimized using outdated single-variable approaches, leaving significant performance potential unrealized. Achieving high expression and durability requires balancing multiple interdependent factors simultaneously: translation dynamics, RNA secondary structure, and genetic element interactions.
RNA Edge was built to solve this multi-dimensional design problem. It's a fully integrated system for optimization of expression profile, with every design validated in application-relevant cell types.
We deliver high-confidence RNA designs in weeks.
Benefits of RNA Edge
End-to-end RNA optimization
- AI sequence optimization, novel genetic parts, and experimental validation to improve expression profile.
Broad therapeutic applicability
- Supports linear mRNA and circular RNA across cell therapy, genome editing, and vaccines.
Proven performance
- Validated in large biopharma programs for CAR and Cas9.
System performance
Data-driven computational and synthetic biology, validated in the lab.
RNA Edge combines proprietary computational models and high-performance genetic parts with integrated screening to deliver validated improvements across the variables that determine therapeutic success.
From sequence to delivery of top candidates
RNA Edge takes your program from sequence design through wet lab validation in weeks, delivering high confidence, data-backed candidates.
Ready to optimize your RNA
therapeutic?
Precise control to drive therapeutic success
Expression profile is a primary determinant of therapeutic success, but achieving the right level, timing, and cell specificity requires optimizing across multiple interdependent biological factors simultaneously. RNA Edge combines proprietary computational models, high-performance genetic parts, and integrated lab screening to systematically explore design space and deliver high-performing candidates across every axis of expression.
Key capabilities
Multi-objective codon optimization
- Up to 9x higher expression by optimizing multiple biological factors.
Genetic parts
- Internal ribosome entry site (IRES) and untranslated region (UTR) design and screening capabilities.
Validation in relevant cells
- Integrated in vitro screening in application-relevant cell models provides greater insight into real-world therapeutic performance.
Why choose RNA Edge?
Models: Proprietary RNA sequence optimization
Traditional codon optimization approaches are simplistic and frequently underperform. Our algorithm balances multiple factors in parallel: translational dynamics, synthesizability, RNA stability, and motif avoidance, to generate sequences with a more complete and balanced expression profile.
Expanded genetic parts capabilities
Off-the-shelf internal ribosome entry site (IRES) elements deliver 4x higher expression than industry standards, supporting circular RNA and multi-transgene constructs. Additionally, AI design and screening capabilities for untranslated regions (UTRs) provide further opportunity to optimize linear mRNA expression.
Lab capabilities: Rapid production and screening
Design flows seamlessly into production, screening, and validation under one roof. Sequence variants are tested in application-relevant cell-based assays, enabling faster design decisions that reflect real-world therapeutic context. Our production and screening capabilities include DNA template generation, RNA generation and purification, cell-based screening and validation, and analytical methods.
Optimization outcomes
Expression level
- Increased expression to achieve the optimal profile.
Duration and stability
- Greater control over RNA half-life and temporal dynamics.
Cell type expression profiling
- Exploration and understanding of differential expression across cell types.
How it works
RNA Edge is an end-to-end integrated platform that delivers top candidates in weeks.
1
AI-guided sequence optimization
Variants generated using Asimov’s proprietary machine learning models, multi-objective codon optimizer, and genetic parts.
2
RNA production
Integrated production and purification of RNA sequence variants.
3
Hit generation primary screen
All variants screened in cell-based assays. Top candidates nominated.
4
Hit-to-lead validation screen
Top hits validated with concentration dependent expression profiling.
5
Delivery of optimized candidates
Optimized sequences transferred with full data package, ready for your next stage.
Ready to optimize your RNA
therapeutic?
Partner case study 1: Anti-CD19 CAR mRNA
9x expression and 4x durability in 12 weeks
A large pharma partner needed to significantly improve expression level and durability of their anti-CD19 CAR mRNA across multiple time points. For CAR-T therapies generated via mRNA rather than viral transduction, both peak expression and duration of CAR persistence on the T cell surface directly impact tumor killing potency and the duration of the therapeutic window, making these the key parameters to optimize for clinical efficacy. RNA Edge generated and screened variants and delivered top candidates to the customer in 12 weeks for further validation in an application relevant LNP formulation.
Objective
- Optimize anti-CD19 CAR mRNA sequence to increase expression level and durability.
Target
- >2x expression vs. benchmark across 24h, 48h, and 72h timepoints.
Outcome
- Achieved 9x expression and 4x durability of the anti-CD19 CAR mRNA, confirmed in partner's hands.
Results
Hit generation primary screening with 45 variants
• Over 95% of variants showed increased expression at 24 hours compared to benchmark
Hit-to-lead validation screening with top 10 hits
• Top candidates achieved 2x expression across all timepoints, with top candidate achieving 9x expression
Partner case study 2: Cas9 mRNA
Increasing burst expression of a Cas9 mRNA sequence
A large pharma partner needed to increase burst expression of a Cas9 mRNA sequence. For in vivo gene editing applications, Cas9 acts transiently; high peak expression shortly after delivery is critical to maximize on-target editing efficiency while minimizing the window for off-target effects. Achieving more protein from less mRNA can also enable lower dosing, improving the therapeutic index and reducing LNP-related toxicity. RNA Edge generated and screened optimized variants and delivered top candidates in 12 weeks.
Objective
- Optimize Cas9 mRNA sequence to increase expression level at 24 hours.
Target
- >2x expression vs. benchmark at 24 hour timepoint.
Outcome
- 2-fold increased expression over benchmark, confirmed in partner's hands.
Results
Hit generation primary screening with 45 variants
• Top variants showed >2x increased expression over benchmark at a fixed dose.
Hit-to-lead validation screening with top hits
• Top candidates confirmed expression increase in full dose range versus benchmark

